$33.9M Series B to Fund Omthera's Omega-3 Product
By Catherine Shaffer
Tuesday, March 15, 2011
Omthera Pharmaceuticals Inc., of Bedminster, N.J., raised $33.9 million in Series B funding and initiated Phase III trials for Epanova, its candidate for high triglycerides. The capital raised will support development of Epanova, which could take a bite out of the $2 billion worldwide market for prescription omega-3 fatty acid.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.